Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
- PMID: 29346604
- DOI: 10.1093/annonc/mdy009
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Abstract
Background: Leptomeningeal metastases (LM) are more frequent in non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Due to limited access to leptomeningeal lesions, the purpose of this study was to explore the potential role of cerebrospinal fluid (CSF) as a source of liquid biopsy in patients with LM.
Patients and methods: Primary tumor, CSF, and plasma in NSCLC with LM were tested by next-generation sequencing. In total, 45 patients with suspected LM underwent lumbar puncture, and those with EGFR mutations diagnosed with LM were enrolled.
Results: A total of 28 patients were enrolled in this cohort; CSF and plasma were available in 26 patients, respectively. Driver genes were detected in 100% (26/26), 84.6% (22/26), and 73.1% (19/26) of samples comprising CSF cell-free DNA (cfDNA), CSF precipitates, and plasma, respectively; 92.3% (24/26) of patients had much higher allele fractions in CSF cfDNA than the other two media. Unique genetic profiles were captured in CSF cfDNA compared with those in plasma and primary tissue. Multiple copy number variations (CNVs) were mainly identified in CSF cfDNA, and MET copy number gain identified in 47.8% (11/23) of patients was the most frequent one, while other CNVs included ERBB2, KRAS, ALK, and MYC. Moreover, loss of heterozygosity (LOH) of TP53 was identified in 73.1% (19/26) CSF cfDNA, which was much higher than that in plasma (2/26, 7.7%; P < 0.001). There was a trend towards a higher frequency of concomitant resistance mutations in patients with TP53 LOH than those without (70.6% versus 33.3%; P = 0.162). EGFR T790M was identified in CSF cfDNA of 30.4% (7/23) of patients who experienced TKI progression.
Conclusion: CSF cfDNA could reveal the unique genetic profiles of LM and should be considered as the most representative liquid biopsy medium for LM in EGFR-mutant NSCLC.
Comment in
-
Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.Ann Oncol. 2018 Apr 1;29(4):789-791. doi: 10.1093/annonc/mdy053. Ann Oncol. 2018. PMID: 29432543 No abstract available.
Similar articles
-
Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.Cancer Biol Ther. 2019;20(4):562-570. doi: 10.1080/15384047.2018.1538614. Epub 2018 Nov 5. Cancer Biol Ther. 2019. PMID: 30395779 Free PMC article.
-
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17. J Thorac Oncol. 2019. PMID: 30659989
-
[Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):646-654. doi: 10.3779/j.issn.1009-3419.2020.102.14. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32838487 Free PMC article. Chinese.
-
Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.Recent Pat Anticancer Drug Discov. 2021;16(1):108-116. doi: 10.2174/1574892815666201127114224. Recent Pat Anticancer Drug Discov. 2021. PMID: 33245275 Review.
-
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4. Lung Cancer. 2017. PMID: 27180141 Review.
Cited by
-
A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.Biomark Med. 2024;18(9):431-439. doi: 10.1080/17520363.2024.2342231. Epub 2024 May 24. Biomark Med. 2024. PMID: 39007837
-
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.NPJ Precis Oncol. 2024 May 28;8(1):121. doi: 10.1038/s41698-024-00582-1. NPJ Precis Oncol. 2024. PMID: 38806586 Free PMC article.
-
Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer.Clin Transl Oncol. 2024 May 25. doi: 10.1007/s12094-024-03507-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38795257
-
A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.Cancer Med. 2024 May;13(10):e7305. doi: 10.1002/cam4.7305. Cancer Med. 2024. PMID: 38770647 Free PMC article.
-
PMS2 amplification contributes brain metastasis from lung cancer.Biol Proced Online. 2024 May 7;26(1):12. doi: 10.1186/s12575-024-00238-1. Biol Proced Online. 2024. PMID: 38714954 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous